Posted on 27 March 2025 by Northern RNA
CALGARY, CANADA – 27 March 2025 – Northern RNA, a leading contract drug manufacturing organization (CDMO) specializing in GMP manufacturing of RNA-based vaccines and therapeutics, today announced the appointment of Dr. John Ballantyne, PhD, to its Board of Directors
“We are pleased to welcome John Ballantyne to our Board of Directors” said Brad Stevens, CEO of Northern RNA. “John is an accomplished and recognized leader in life sciences and biomanufacturing. His extensive experience will be invaluable as we continue to expand our organization, our products and our services to meet growing market demands”
John Ballantyne brings over 20 years of executive and board leadership experience to Northern RNA, having co-founded Aldevron in 1998 and serving as its Chief Science Officer through its acquisition by Danaher Corporation for $9.6 Billion. Following his retirement from Aldevron, Dr. Ballantyne has continued his significant presence in the biotechnology sector through hisinvestments, Board and Scientific Advisory Board roles, and co-founding of multiple companies in the life sciences space.
“Dr. Ballantyne brings a wealth of executive and Director biotech experience to Northern RNA” said Michael Crothers, Board Chair of Northern RNA “and John has been highly successful in growing value for shareholders and investors”
Dr. Ballantyne holds undergraduate degrees in Pharmacy from the Central Institute of Technology (Heretaunga, NZ) and University of Otago (Dunedin, NZ) and his Doctorate in Pharmaceutical Sciences from North Dakota State University (Fargo, ND).
“I’m excited to be joining the Board of such a dynamic and growing company” said John Ballantyne. “Northern RNA is a leading CDMO with a focus on supporting personalized and precision medicines and rare diseases. I look forward to helping the organization continue its strategic growth”
About Northern RNA
Founded in 2020 to address unmet global demand for the manufacturing of vaccines and vaccinecomponents, Northern RNA is a leading Contract Development and Manufacturing Organization(CDMO) specializing in the production of nucleic acid products used in applications including mRNA vaccines, DNA vaccines, mRNA therapies, gene editing, and gene therapies. Our goal is to provide secure, clinical-to-commercial scale, GMP-grade manufacturing for our customers across the globe. For more information about our end-to-end CDMO capabilities, please follow us on
LinkedIn or visit us at www.northernrna.com.
#CDMO #RNA #mRNA #LNP #Lipids #oligo #Biomanufacturing #DrugDevelopment #CancerTherapy #Immunotherapy #Oncology #ManufacturingABetterFuture